Dr Reddy’s Laboratories Ltd has entered into an agreement with Australia’s Alchemia Ltd, a drug discovery and development company, to buy worldwide exclusive intellectual property rights of its generic anti-coagulant drug fondaparinux sodium for a cash consideration of $17.5 million (Rs 116 crore).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
